Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12407911 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL16027502 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL13956209 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL18511226 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL500473 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL13112800 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL22330780 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL22129916 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL1087871 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 | |
| SCHEMBL2174263 | 0.83 | BCHE (0.56) | BCHEACHETACR2LMNAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110066302-B | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-03-04 | — | — | US | disclosed |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| WO-2021004498-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-01-14 | — | — | WO | disclosed |
| CN-112209908-A | Glucopyranosyl derivative and use thereof | 东莞市东阳光新药研发有限公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3747892-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| CN-111630058-A | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2019149178-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | 广东东阳光药业有限公司 | 2019-08-08 | — | — | WO | disclosed |
| WO-2019144864-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | ALDH1A1 995/4885TSHR 4319/4885BCHE 4184/4885 |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | ALDH1A1 995/4885TSHR 4319/4885BCHE 4184/4885 |
| US-11186602-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | ALDH1A1 703/4885TSHR 4291/4885BCHE 3734/4885 |
| US-20210054013-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | ALDH1A1 703/4885TSHR 4291/4885BCHE 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.